BR112013033941A2 - composição oftálmica para tratamento de problemas oculares, preparação, sólução, gel, pomada, emulsão ou tira estéril, e método de preparação de composição oftálmica - Google Patents

composição oftálmica para tratamento de problemas oculares, preparação, sólução, gel, pomada, emulsão ou tira estéril, e método de preparação de composição oftálmica

Info

Publication number
BR112013033941A2
BR112013033941A2 BR112013033941A BR112013033941A BR112013033941A2 BR 112013033941 A2 BR112013033941 A2 BR 112013033941A2 BR 112013033941 A BR112013033941 A BR 112013033941A BR 112013033941 A BR112013033941 A BR 112013033941A BR 112013033941 A2 BR112013033941 A2 BR 112013033941A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
ointment
solidification
emulsion
gel
Prior art date
Application number
BR112013033941A
Other languages
English (en)
Inventor
Gallois - Bernos Annabelle
L Davis Carrie
Lu Fang
F Molock Frank Jr
K Young James
Osborn Lorenz Kathy
L Canavan Kristy
Original Assignee
Johnson & Johnson Vision Care
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Vision Care filed Critical Johnson & Johnson Vision Care
Publication of BR112013033941A2 publication Critical patent/BR112013033941A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eyeglasses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013033941A 2011-06-30 2012-06-19 composição oftálmica para tratamento de problemas oculares, preparação, sólução, gel, pomada, emulsão ou tira estéril, e método de preparação de composição oftálmica BR112013033941A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503158P 2011-06-30 2011-06-30
US13/495,049 US10383839B2 (en) 2011-06-30 2012-06-13 Esters for treatment of ocular inflammatory conditions
PCT/US2012/043078 WO2013003113A1 (en) 2011-06-30 2012-06-19 Esters for treatment of ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
BR112013033941A2 true BR112013033941A2 (pt) 2017-02-14

Family

ID=47391255

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013034054A BR112013034054A2 (pt) 2011-06-30 2012-06-19 ésteres para tratamento de condições inflamatórias oculares
BR112013033941A BR112013033941A2 (pt) 2011-06-30 2012-06-19 composição oftálmica para tratamento de problemas oculares, preparação, sólução, gel, pomada, emulsão ou tira estéril, e método de preparação de composição oftálmica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112013034054A BR112013034054A2 (pt) 2011-06-30 2012-06-19 ésteres para tratamento de condições inflamatórias oculares

Country Status (14)

Country Link
US (7) US10383839B2 (pt)
EP (3) EP3556346B1 (pt)
JP (4) JP6282586B2 (pt)
KR (4) KR20190108650A (pt)
CN (5) CN103813783A (pt)
AR (2) AR086825A1 (pt)
AU (10) AU2012275759A1 (pt)
BR (2) BR112013034054A2 (pt)
CA (2) CA2840155C (pt)
ES (1) ES2743174T3 (pt)
PL (1) PL3556346T3 (pt)
RU (8) RU2627438C2 (pt)
TW (4) TWI633883B (pt)
WO (2) WO2013003114A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104684389A (zh) 2012-05-10 2015-06-03 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
MA41912A (fr) * 2015-04-07 2018-02-13 Hyalblue S R L Esters de glycosaminoglycane, procédés pour leur préparation et leur utilisation dans des formulations à usage ophtalmique
RU2737893C2 (ru) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN108096181A (zh) * 2018-02-05 2018-06-01 西安医学院 Dha、epa在制备治疗干眼症的口服药物的应用
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
CA3136137A1 (en) * 2019-04-04 2020-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
CN116018532A (zh) * 2020-08-10 2023-04-25 博士伦爱尔兰有限公司 包装溶液
US20220411115A1 (en) * 2021-05-26 2022-12-29 Bausch + Lomb Ireland Limited Packaging solutions
WO2023049791A1 (en) * 2021-09-22 2023-03-30 The Trustees Of Columbia University In The City Of New York Delivery systems for bioactive lipids

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577446A (en) 1968-09-09 1971-05-04 American Home Prod Phosphatidylalkanolamine derivatives
US4330383A (en) 1978-07-18 1982-05-18 Polymer Technology Corporation Dimensionally stable oxygen permeable hard contact lens material and method of manufacture
ES484553A1 (es) 1978-10-05 1980-05-16 Hoechst Ag Un metodo para preparar 4-fenil-1,3-benzodiazepinas
US4495313A (en) 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
JPS60110855A (ja) 1983-11-17 1985-06-17 Toshiba Corp 装飾部品の製造方法
JPS6123860A (ja) 1984-07-12 1986-02-01 Yamaha Motor Co Ltd 多気筒エンジンの給気装置
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
DE3704825A1 (de) 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US4889664A (en) 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US5039459A (en) 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US4915974A (en) 1989-02-17 1990-04-10 Nabisco Brands, Inc. Polyvinyl oleate as a fat replacement
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH06123860A (ja) 1992-10-09 1994-05-06 Tokyo Keikaku:Kk 酸素透過性ハードコンタクトレンズ
US5472703A (en) 1993-03-02 1995-12-05 Johnson & Johnson Vision Products, Inc. Ophthalmic lens with anti-toxin agent
US5337888A (en) * 1993-09-01 1994-08-16 Morrison Robert J Contact lens case
US5460802A (en) * 1994-07-18 1995-10-24 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
US7468398B2 (en) 1994-09-06 2008-12-23 Ciba Vision Corporation Extended wear ophthalmic lens
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
DE19511322C2 (de) 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
TW585882B (en) 1995-04-04 2004-05-01 Novartis Ag A method of using a contact lens as an extended wear lens and a method of screening an ophthalmic lens for utility as an extended-wear lens
EP0968727B1 (en) 1997-12-02 2008-07-30 Hoya Corporation Intraocular lenses and process for producing molded-in type intraocular lenses
FR2772033A1 (fr) 1997-12-05 1999-06-04 Essilor Int Procede de fabrication d'un materiau polymere transparent resistant au depot de proteines, materiau obtenu par ce procede, lentilles de contact et implants intraoculaires faits de ce materiau
CA2320807C (en) 1998-02-11 2011-01-18 Research Triangle Pharmaceuticals Method and composition for treatment of inflammatory conditions
US5998498A (en) 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US7052131B2 (en) 2001-09-10 2006-05-30 J&J Vision Care, Inc. Biomedical devices containing internal wetting agents
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
JP2000010055A (ja) 1998-06-19 2000-01-14 Seed Co Ltd 親水性眼用レンズ及びその製造方法
JP3824791B2 (ja) 1998-10-01 2006-09-20 株式会社ニデック 眼内レンズの製造方法
CN1173194C (zh) 1998-10-13 2004-10-27 法玛西雅格罗宁根有限公司 可注射的眼内镜片
SE9803481D0 (sv) 1998-10-13 1998-10-13 Pharmacia & Upjohn Ab Photocurable siloxane polymers
US6291519B1 (en) 1998-10-14 2001-09-18 Novartis Ag Method of preventing damage to eye tissue
EP1137956A1 (en) 1998-10-29 2001-10-04 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions
US7297214B2 (en) * 1999-09-03 2007-11-20 Kiyohito Ishida Free cutting alloy
ATE258791T1 (de) 1999-11-09 2004-02-15 Alcon Inc Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
AU2603301A (en) 1999-12-22 2001-07-03 Alcon Universal Limited 6-keto prostaglandin F1alpha and analogs for treating dry eye
JP4434397B2 (ja) * 1999-12-28 2010-03-17 株式会社シード 軟質眼用レンズ
IL134240A0 (en) 2000-01-27 2001-04-30 Senyorina Ltd Inositol derivatives and their pharmaceutical use
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6531432B2 (en) 2000-12-07 2003-03-11 Johnson & Johnson Vision Care, Inc. Contact lens packaging solutions
CA2448896C (en) 2001-05-30 2010-12-21 Yeda Research And Development Co. Ltd. Allylmercaptocaptopril compounds and uses thereof
CN1267174C (zh) * 2001-12-12 2006-08-02 马泰克生物科学博尔德公司 从含油种子和微生物来源提取和冬化脂类的方法
WO2003105776A2 (en) 2002-06-17 2003-12-24 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
JPWO2004004738A1 (ja) 2002-07-02 2005-11-04 わかもと製薬株式会社 角結膜上皮細胞障害治療薬又は予防薬
US20050124699A1 (en) 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20050054723A1 (en) 2003-05-27 2005-03-10 Johan Stjernschantz Method for the treatment of glaucoma and ocular hypertension with prostaglandin analogues without melanogenic side effect
FR2857770B1 (fr) * 2003-07-18 2005-10-21 Valois Sas Indicateur de doses ameliore pour dispositif de distribution de produit fluide.
US20050103466A1 (en) 2003-11-19 2005-05-19 Landry Kenneth D. Refrigerator-oven
US20050220742A1 (en) 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
NZ552481A (en) * 2004-07-01 2008-12-24 Schepens Eye Res Compositions and methods for treating eye disorders and conditions
US7553860B2 (en) 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
US20100105773A1 (en) 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
GB0623299D0 (en) 2006-11-22 2007-01-03 Sauflon Cl Ltd Contact lens
US20080161275A1 (en) 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
RU2336851C1 (ru) 2007-06-21 2008-10-27 Эрнест Витальевич Бойко Мягкая контактная линза
WO2009025763A2 (en) 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
TWI551305B (zh) 2007-08-31 2016-10-01 諾華公司 相對黏稠封裝溶液之用途
CN103191129A (zh) 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
US7884141B2 (en) 2007-11-14 2011-02-08 Bausch & Lomb Incorporated Biomedical devices
BRPI0821158A2 (pt) * 2007-12-20 2015-06-16 Novartis Ag Método para fazer lentes de contato
US20100105772A1 (en) 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
TWI506333B (zh) 2008-12-05 2015-11-01 Novartis Ag 用以傳遞疏水性舒適劑之眼用裝置及其製造方法
WO2010103402A1 (en) 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
JP6123860B2 (ja) 2015-09-17 2017-05-10 王子ホールディングス株式会社 ベルト型使い捨ておむつ
JP2017195808A (ja) * 2016-04-27 2017-11-02 三菱ケミカル株式会社 カンゾウ属植物の育成方法

Also Published As

Publication number Publication date
AU2019204333A1 (en) 2019-07-11
US11311510B2 (en) 2022-04-26
RU2640506C9 (ru) 2018-05-11
RU2019137026A (ru) 2021-05-19
CN107260716A (zh) 2017-10-20
TWI633883B (zh) 2018-09-01
RU2640506C2 (ru) 2018-01-09
TW201315465A (zh) 2013-04-16
CA2840152A1 (en) 2013-01-03
RU2014102958A (ru) 2015-08-10
US20190328698A1 (en) 2019-10-31
RU2014102996A (ru) 2015-08-10
TW201906596A (zh) 2019-02-16
JP6675361B2 (ja) 2020-04-01
KR20140146037A (ko) 2014-12-24
EP3556346A1 (en) 2019-10-23
CN103796635A (zh) 2014-05-14
CN108969471A (zh) 2018-12-11
US8865685B2 (en) 2014-10-21
AU2017204759B2 (en) 2019-03-07
TW201818920A (zh) 2018-06-01
AU2020204211A1 (en) 2020-07-16
AU2022202729A1 (en) 2022-05-19
RU2018133283A3 (pt) 2020-03-20
AU2019203920B2 (en) 2020-05-14
RU2018133283A (ru) 2020-03-20
KR102023326B1 (ko) 2019-11-04
CA2840152C (en) 2021-06-08
ES2743174T3 (es) 2020-02-18
AU2012275760B2 (en) 2017-08-03
JP2014518262A (ja) 2014-07-28
TWI587857B (zh) 2017-06-21
KR20190108650A (ko) 2019-09-24
US20200222357A1 (en) 2020-07-16
RU2017125922A (ru) 2019-01-31
AU2012275760A1 (en) 2014-01-23
EP2726061B1 (en) 2017-02-22
AU2017204838B9 (en) 2021-09-09
AU2017204838B2 (en) 2019-03-21
TWI713867B (zh) 2020-12-21
EP2726061A1 (en) 2014-05-07
RU2017142720A (ru) 2019-06-07
RU2707961C2 (ru) 2019-12-03
PL3556346T3 (pl) 2022-01-31
CN103813783A (zh) 2014-05-21
RU2747953C2 (ru) 2021-05-17
KR20190108648A (ko) 2019-09-24
KR20140048947A (ko) 2014-04-24
BR112013034054A2 (pt) 2017-02-07
CN108272783A (zh) 2018-07-13
KR102203310B1 (ko) 2021-01-15
RU2673230C1 (ru) 2018-11-23
WO2013003114A8 (en) 2013-07-25
US20200206178A1 (en) 2020-07-02
AU2017204838A1 (en) 2017-08-03
US11096919B2 (en) 2021-08-24
AU2019204333A8 (en) 2019-08-22
EP2726058A1 (en) 2014-05-07
EP3556346B1 (en) 2021-10-13
AU2017204759A1 (en) 2017-07-27
RU2017125922A3 (pt) 2019-01-31
RU2018136873A3 (pt) 2020-04-20
RU2018136873A (ru) 2020-04-20
AU2020281097A1 (en) 2021-01-07
AU2012275759A1 (en) 2014-01-23
US10383839B2 (en) 2019-08-20
AU2019203920A1 (en) 2019-06-20
JP2019178150A (ja) 2019-10-17
JP2014518261A (ja) 2014-07-28
KR102022838B1 (ko) 2019-09-20
JP2018065792A (ja) 2018-04-26
JP6282586B2 (ja) 2018-02-21
AU2022228206A1 (en) 2022-10-06
CA2840155C (en) 2021-09-14
AR086824A1 (es) 2014-01-22
EP2726058B1 (en) 2019-06-19
WO2013003113A1 (en) 2013-01-03
US20210379005A1 (en) 2021-12-09
CN108272783B (zh) 2020-11-17
US10588887B2 (en) 2020-03-17
US20130005691A1 (en) 2013-01-03
JP6352177B2 (ja) 2018-07-04
TW201315464A (zh) 2013-04-16
US20140364400A1 (en) 2014-12-11
RU2017142720A3 (pt) 2019-06-07
US20130005805A1 (en) 2013-01-03
RU2627438C2 (ru) 2017-08-08
AR086825A1 (es) 2014-01-22
WO2013003114A1 (en) 2013-01-03
CA2840155A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
BR112013033941A2 (pt) composição oftálmica para tratamento de problemas oculares, preparação, sólução, gel, pomada, emulsão ou tira estéril, e método de preparação de composição oftálmica
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
HK1203478A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
BR112013023816A2 (pt) solução ou formulação estabilizada, seu método de preparação, métodos de aplicação e usos
BR112014003681A2 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112014012565A2 (pt) aparelho para tratamento de pele, e, método de operar aparelho para tratamento de pele
BR112014028368A2 (pt) método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
BR112013029203A2 (pt) método para a preparação de um ou mais oligossacarídeos de leite humano, e, uso de oligossacarídeos de leite humano
BR112014008483A2 (pt) sistema de laser para cirurgia ocular, conjunto de dispositivos de interface, uso de um conjunto de dispositivos de interface, e, método para tratamento ocular cirúrgico com laser
DK2895621T3 (da) Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
BR112014009817A2 (pt) sistema e método para identificação de doenças oftamológicas
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2848097T3 (da) Anordning til plasmabehandlingen af humane, animalske eller plante overflader, især af hud eller slimhinde områder
BR112013031685A2 (pt) formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
SG11201503231YA (en) METHODS OF TREATING <i>S. AUREUS</i>-ASSOCIATED DISEASES
EP3086809A4 (en) Compositions and methods of treating ocular diseases
BR112015015054A2 (pt) gel, solução, emulsão, ou dispersão antisséptica antiborboto para as mãos; composição antisséptica antiborboto para fricção nas mãos; formulação antiborboto; e método para melhorar a sensação na pele de uma composição antisséptica para fricção nas mãos
BR112013029514A2 (pt) composição imunogênica, vacina, e, método de tratar ou impedir uma doença
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
PL3193832T3 (pl) Lepkosprężysty preparat do stosowania w metodach chirurgicznych w chirurgii ocznej
BR112014013807A2 (pt) composição de condicionamento de tecidos e processo para o tratamento de tecido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/00 , A61K 31/16 , A61K 31/201 , A61K 31/202 , A61K 31/203 , A61K 31/557 , A61P 27/02 , A61P 27/04

Ipc: A61K 31/232 (2006.01), A61K 9/08 (2006.01), A61K 9

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL